Company & Sponsor Intelligence
Jazz Pharmaceuticals
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed1
Countries1
Therapeutic footprint
anxietyepilepsy
Indexed studies
NCT05288283Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT00106860A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
anxiety · United StatesPHASE3
anxiety · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →